Zaid Baha, DO
Psychiatry · Flint, MINPI 1447604608
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,570 of the $13,583 with a category attached, or 77.8%. 14 manufacturers reported payments, led by AbbVie at 47.5% of the total. 2025 is the largest year on record at $8,013, more than ten times the $269 reported in 2019. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $103.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Teva Pharmaceuticals USA, Inc.$5K
- Alkermes, Inc.$552
- E.r. Squibb & Sons, L.L.C.$347
- Otsuka America Pharmaceutical, Inc.$313
- Johnson & Johnson$299
- plus $672 from 8 others
What the payments were for
- Speaking & faculty fees$10,57078%
- Food & beverage$2,90221%
- Education$1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $6,453 |
| Teva Pharmaceuticals USA, Inc. | 11 | $4,947 |
| Alkermes, Inc. | 27 | $552 |
| E.r. Squibb & Sons, L.L.C. | 11 | $347 |
| Otsuka America Pharmaceutical, Inc. | 13 | $313 |
| Johnson & Johnson | 11 | $299 |
| Indivior Inc. | 13 | $270 |
| Neurocrine Biosciences, Inc. | 6 | $144 |
| Avanir Pharmaceuticals, Inc. | 2 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| USWM, LLC | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,583 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 21 | $343 |
| Olanzapine | 12 | $254 |
| Prazosin Hcl | 16 | $194 |
| Trazodone Hcl | 22 | $124 |
| Lorazepam | 25 | $115 |
| Lamotrigine | 32 | $113 |
| Hydroxyzine Pamoate | 11 | $101 |
| Clonidine Hcl | 26 | $87 |
| Lithium Carbonate | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Flint
- Anjana BhranyFlint$12K
- Nikhil VoraFlint$10K
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.